Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Other News

Displaying 1 to 10 of 16 Posts . Displaying 10 of Posts . Page of 2 . Go To Page: . Per Page: . . . View All Sort By: .

CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with...

Read More

Novartis first-in-class Cosentyx® approved in China for psoriasis patients

Novartis first-in-class Cosentyx® approved in China for psoriasis patients China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis...

Read More

AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan This marks the first regulatory approval globally for SKYRIZI™ (risankizumab) SKYRIZI is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit[1] NORTH CHICAGO, Ill., March 26, 2019 /PRNewswire/...

Read More

French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults published in the JEADV

Abstract These guidelines were developed by the psoriasis research group of the French Society of Dermatology with the aim of providing updated decision‐making algorithms for the systemic treatment of adult patients with moderate‐to‐severe psoriasis. Our algorithms were generated after rigorous evaluation of existing guidelines on the treatment of psoriasis and of publications concerning new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines...

Read More

The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines for treating psoriasis

Developed by an expert workgroup composed of several dermatologists, as well as a cardiologist, a rheumatologist and patient representatives, the guidelines appear in the Journal of the American Academy of Dermatology. One guideline focuses on the other health conditions that may be associated with the disease, including psoriatic arthritis, cardiovascular disease, metabolic syndrome and inflammatory bowel disease. This guideline also addresses the increased risk of anxiety and depression in...

Read More

TV Host and Fashion Journalist Louise Roe Shares Her Personal Story With Plaque Psoriasis as Part of INSIDE PERSPECTIVE Campaign

TV host and fashion journalist Louise Roe launches the INSIDE PERSPECTIVE campaign with Celgene Corporation (NASDAQ: CELG) and Otezla® (apremilast), and for the first time, shares her inside story with psoriasis, a condition she has been living with for more than a decade.

Read More

Sun Pharma Announces the Availability of ILUMYATM (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that moderate-to-severe psoriasis treatment ILUMYATM (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYATM is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Read More

The European Commission approves Almirall’s ILUMETRI® (tildrakizumab) for moderate-to-severe chronic plaque psoriasis

Almirall, S.A. announced today that the European Commission (EC) has approved ILUMETRI® (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy1.

Read More

Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Psoriasis

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.

Read More

Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).

Read More
UPCOMING EVENT

Challenging cases in psoriasis:
A focus on paradigms, children, non-cicatricial alopecia, and individualized treatment

Thursday, may 3, 2019
2:30 pm – 11:30 pm
buenos aires, argentina
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

This website uses cookies. Please ensure your cookies are enabled. 
OK